(EMAILWIRE.COM, October 13, 2017 ) Browse 369 market data tables and 46 figures spread through 312 pages and in-depth TOC on “Active Pharmaceutical Ingredients/API Market”
http://www.marketsandmarkets.com/Market-Reports/API-Market-263.html
Early buyers will receive 10% customization on this report.

Prominent players in the Active pharmaceutical ingredients market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.) and AbbVie Inc. (U.S.).

The Active pharmaceutical ingredients market is highly competitive and fragmented with many big and small players as well as contract manufacturing organizations. Pfizer, Inc., a leading player in the APIs market.

Pfizer’s leading position in the market can be attributed to its exhaustive product portfolio spread across its business segments includng Global Innovative Pharmaceuticals (GIP); Global Established Pharmaceuticals (GEP); and Global Vaccines, Oncology. As part of its growth strategy, the company focuses on adopting both organic and inorganic growth strategies such as agreements, partnerships, collaborations, approvals, and acquisitions.

In accordance with this, in June 2016, Pfizer acquired Anacor Pharmaceuticals, Inc. (U.S.), a leading biopharmaceutical company developing small molecule therapeutics. Moreover, in September 2015, Pfizer acquired Hospira (U.S.), a global leader in biosimilars. This acquisition enabled the company to broaden its products offerings.
Novartis International AG (Switzerland), is another leading player in this market.

Talk to Our Research Experts@
http://www.marketsandmarkets.com/speaktoanalyst.asp?id=263

The company’s strengths lie in its strong brand recognition and robust product portfolio. the company invests a significant amount of its revenue in R&D activities. In 2015, the company invested 18.0% of its total revenue (USD 8.9 billion) on R&D. This significant investment in R&D enables the company to launch innovative and technologically advanced products in the market.

Novartis also focuses on inorganic growth strategies to sustain its foothold in the market. For instance, in June 2016, Novartis entered into a licensing and collaboration agreement with Xencor (U.S.), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer.

The key strategies followed by most companies in the Active pharmaceutical ingredients market are agreements, collaborations, partnerships, joint ventures, and alliances; regulatory approvals, mergers and acquisitions; expansions and investments.

Among all growth strategies adopted by market players, agreements, collaborations, partnerships, joint ventures, and alliances accounted for the largest share of the overall growth strategies mapped from 2013 to 2016. Some leading players adopting these strategies include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Merck & Co., Inc. (U.S.).

Related Reports:

1. Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology (Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics, Immunosuppressants), End User (Hospital Labs, Private Labs) - Global Forecast to 2020.
http://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html

2. High Potency API /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech (Biologic, Biosimilar)), Manufacturer (Captive, Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) - Global Forecast to 2021.
http://www.marketsandmarkets.com/Market-Reports/high-potency-api-market-36582475.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street,
Suite 2175, Seattle,
WA 98101, United States
1-888-600-6441
Email: sales@marketsandmarkets.com